Payment overview · 2025
General Payments
$1,049.45
48 reported records · 11 companies
Healthcare provider profile · identity verified
Marvin E Urbina, MD
Allopathic & Osteopathic Physicians|Family Medicine · BALDWIN PARK, CA · NPI 1225129281
Verified facts
What the public records show
CMS Open Payments records show Marvin E Urbina, MD received $1,049.45 in general payments during 2025 across 48 reported records.
Madrigal Pharmaceuticals accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $279.25 | 26.6% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $253.12 | 24.1% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.34 | 16.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.37 | 8.2% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $81.20 | 7.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.70 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.42 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.65 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.28 | 2.6% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $26.78 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.34 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,049.45 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $279.25 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $157.14 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $149.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.33 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.48 | 9 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $81.20 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.15 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 124 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
124 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
67 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1269 | 451 |
| Amlodipine Besylate | Amlodipine Besylate | 830 | 280 |
| Losartan Potassium | Losartan Potassium | 572 | 189 |
| Metformin Hcl | Metformin Hcl | 562 | 218 |
| Lisinopril | Lisinopril | 443 | 172 |
| Gabapentin | Gabapentin | 427 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 146 |
| Omeprazole | Omeprazole | 336 | 145 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 118 |
| Benazepril Hcl | Benazepril Hcl | 290 | 105 |
| Furosemide | Furosemide | 256 | 93 |
| Glipizide | Glipizide | 254 | 102 |
| Sertraline Hcl | Sertraline Hcl | 247 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 100 |
| Carvedilol | Carvedilol | 203 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 66 |
| Ibuprofen | Ibuprofen | 187 | 88 |
| Montelukast Sodium | Montelukast Sodium | 175 | 78 |
| Alendronate Sodium | Alendronate Sodium | 173 | 69 |
| Famotidine | Famotidine | 156 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 61 |
| Allopurinol | Allopurinol | 147 | 57 |
| Glipizide Er | Glipizide | 147 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 46 |
| Farxiga | Dapagliflozin Propanediol | 124 | 35 |
| Eliquis | Apixaban | 122 | 42 |
| Januvia | Sitagliptin Phosphate | 120 | 28 |
| Tramadol Hcl | Tramadol Hcl | 120 | 38 |
| Glimepiride | Glimepiride | 117 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 114 | 69 |
| Ozempic | Semaglutide | 111 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 53 |
| Trazodone Hcl | Trazodone Hcl | 99 | 33 |
| Azithromycin | Azithromycin | 97 | 85 |
| Ketoconazole | Ketoconazole | 97 | 53 |
| Celecoxib | Celecoxib | 91 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 28 |
| Mirtazapine | Mirtazapine | 84 | 29 |
| Rybelsus | Semaglutide | 84 | 21 |
| Simvastatin | Simvastatin | 82 | 30 |
| Baclofen | Baclofen | 79 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 36 |
| Clonidine Hcl | Clonidine Hcl | 76 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 25 |
| Atenolol | Atenolol | 75 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 23 |
| Fenofibrate | Fenofibrate | 74 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 21 |
| Donepezil Hcl | Donepezil Hcl | 67 | 30 |
| Gemtesa | Vibegron | 67 | 23 |
| Linzess | Linaclotide | 63 | 18 |
| Prednisone | Prednisone | 63 | 38 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 19 |
| Xarelto | Rivaroxaban | 56 | 18 |
| Febuxostat | Febuxostat | 55 | 23 |
| Meclizine Hcl | Meclizine Hcl | 55 | 33 |
| Nabumetone | Nabumetone | 54 | 29 |
| Folic Acid | Folic Acid | 52 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Risperidone | Risperidone | 50 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 48 | 19 |
| Valsartan | Valsartan | 47 | 20 |
| Alprazolam | Alprazolam | 46 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 15 |
| Jardiance | Empagliflozin | 46 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 29 |
| Finasteride | Finasteride | 43 | 19 |
| Nifedipine Er | Nifedipine | 42 | 14 |
| Naproxen | Naproxen | 41 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 36 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 38 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 31 |
| Enalapril Maleate | Enalapril Maleate | 36 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 12 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 17 |
| Dexamethasone | Dexamethasone | 32 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 15 |
| Spironolactone | Spironolactone | 32 | 12 |
| Dutasteride | Dutasteride | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 17 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 15 |
| Amoxicillin | Amoxicillin | 28 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Colchicine | Colchicine | 28 | 16 |
| Latanoprost | Latanoprost | 28 | 11 |
| Nitroglycerin | Nitroglycerin | 28 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 16 |
| Promethazine Hcl | Promethazine Hcl | 27 | 27 |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 14 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | 11 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 11 |
| Cromolyn Sodium | Cromolyn Sodium | 21 | 13 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 17 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | 12 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,049.45 · 48 records | Madrigal Pharmaceuticals | ACCRUFER, AIRSUPRA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, GVOKE HYPOPEN, KEVEYIS, KISUNLA, OTEZLA, Ozempic, REPATHA, REZDIFFRA, Wegovy, Xhance | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error